Beating Cancer Is Still An Everything-But-Easy Challenge That Pharmaceutical Companies Cannot Solve Overnight
Beating Cancer Is Still An Everything-But-Easy Challenge That Pharmaceutical Companies Cannot Solve Overnight
戰勝癌症仍然是一項極具挑戰的任務，藥品公司無法夜盤即成。
On Tuesday, Merck Group revealed an unexpected decision to end a Phase III trial of its cancer drug Xevinapant. This move threatens to undermine confidence the research abilities of the Darmstadt, Germany-based company that is not related to the U.S-based Merck & Co (NYSE:MRK).
默克製藥公司週二表示，其抗癌藥物Xevinapant的3期臨床試驗將取消，令德國達姆施塔特的默克集團的研究能力受到威脅。與位於美國的默克及公司（紐交所代碼:MRK）無任何關聯。
Merck & Co continues its quest to end cancer.
默克及公司繼續努力終結癌症。
Meanwhile, Merck & Co just reported first-time positive data for its antibody-drug conjugate therapy aimed at lung and breast cancer patients from its open-label Phase II trial.
同時，默克及公司剛剛公佈了第二期開放標籤試驗，針對肺癌和乳腺癌患者的抗體藥物聯結療法的首次陽性數據。
At the beginning of June, Merck also released more good news from its...
6月初，默克還發布了一項利...
登入免費觀看全文
登入/註冊
資訊熱榜
更新時間